Abstract：
OBJECTIVE: Cryoprecipitated antihemophilic factor (cryo) has been used for fibrinogen replacement in actively bleeding patients, dysfibrinogenemia, and hypofibrinogenemia. Cryo has a shelf life of 4 to 6 hours after thawing and a long turnaround time in issuing the product, posing a major limitation of its use. Recently, the US Food and Drug Administration approved Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex [IFC]) for the treatment of bleeding associated with fibrinogen deficiency, which can be stored at room temperature and has a shelf life of 5 days after thawing.
METHODS: We identified locations and specific end users with high cryoprecipitate utilization and waste. We partnered with our blood supplier to use IFC in these locations. We analyzed waste and turnaround time before and after implementation.
RESULTS: Operative locations had a waste rate that exceeded nonoperative locations (16.7% vs 3%) and were targeted for IFC implementation. IFC was added to our inventory to replace all cryo orders from adult operating rooms, and waste decreased to 2.2% in these locations. Overall waste of cryoprecipitated products across all locations was reduced from 8.8% to 2.4%. The turnaround time for cryoprecipitated products was reduced by 58% from 30.4 minutes to 14.6 minutes.
CONCLUSIONS: There has been a substantial decrease in waste with improved turnaround time after IFC implementation. This has improved blood bank logistics, improved efficiency of patient care, and reduced costly waste.
METHODS: We identified locations and specific end users with high cryoprecipitate utilization and waste. We partnered with our blood supplier to use IFC in these locations. We analyzed waste and turnaround time before and after implementation.
RESULTS: Operative locations had a waste rate that exceeded nonoperative locations (16.7% vs 3%) and were targeted for IFC implementation. IFC was added to our inventory to replace all cryo orders from adult operating rooms, and waste decreased to 2.2% in these locations. Overall waste of cryoprecipitated products across all locations was reduced from 8.8% to 2.4%. The turnaround time for cryoprecipitated products was reduced by 58% from 30.4 minutes to 14.6 minutes.
CONCLUSIONS: There has been a substantial decrease in waste with improved turnaround time after IFC implementation. This has improved blood bank logistics, improved efficiency of patient care, and reduced costly waste.
摘要：
目的：冷沉淀抗血友病因子（cryo）已用于积极出血患者的纤维蛋白原替代，纤维蛋白原异常血症，和低纤维蛋白原血症。Cryo在解冻后的保质期为4至6小时，并且在发行产品时需要很长的周转时间，构成其使用的主要限制。最近,美国食品和药物管理局批准病原体减少冷冻沉淀纤维蛋白原复合物（INTERCEPT纤维蛋白原复合物[IFC]）用于治疗与纤维蛋白原缺乏相关的出血，它可以在室温下储存，解冻后的保质期为5天。
方法：我们确定了具有高冷沉淀利用率和废物的位置和特定最终用户。我们与我们的血液供应商合作，在这些地点使用IFC。我们分析了实施前后的浪费和周转时间。
结果：手术地点的浪费率超过了非手术地点（16.7%对3%），并且是IFC实施的目标。IFC被添加到我们的库存中，以取代成人手术室的所有冷冻订单，这些地方的废物减少到2.2%。所有地点的冷沉淀产物的总废物从8.8%减少到2.4%。冷沉淀产物的周转时间从30.4分钟减少58%至14.6分钟。
结论：IFC实施后，随着周转时间的延长，废物大幅减少。这改善了血库的后勤，提高患者护理效率，减少昂贵的浪费。
方法：我们确定了具有高冷沉淀利用率和废物的位置和特定最终用户。我们与我们的血液供应商合作，在这些地点使用IFC。我们分析了实施前后的浪费和周转时间。
结果：手术地点的浪费率超过了非手术地点（16.7%对3%），并且是IFC实施的目标。IFC被添加到我们的库存中，以取代成人手术室的所有冷冻订单，这些地方的废物减少到2.2%。所有地点的冷沉淀产物的总废物从8.8%减少到2.4%。冷沉淀产物的周转时间从30.4分钟减少58%至14.6分钟。
结论：IFC实施后，随着周转时间的延长，废物大幅减少。这改善了血库的后勤，提高患者护理效率，减少昂贵的浪费。
